Provided by Tiger Trade Technology Pte. Ltd.

AI Healthcare

681.25
+7.901.17%
Number of Gainers:4
Number of Losers:- -
Number of Flat:- -
PE:- -
High:693.19
Open:674.36
Low:674.36
Close:673.35
Volume:4.46M
Turnover:186.69M
Market Cap:21.86B
Float Cap:16.76B

Loading ...

Danaher’s IDT, Aldevron launch research grade S.p. Cas9 mRNA, SpyFi

TIPRANKS
·
1 hour ago

ETF Daily | CRCD Surges 22%; TEMT Jumps 22%; ERX Climbs 4%; XRPT, UXRP, XXRP Sink 23%; Energy ETFs Lead Gains

ETF Tracker
·
13 hours ago

Tempus AI Inc Stock (TEM) Moved Up by 7.35% on Sep 15: What Investors Need To Know

TradingKey
·
19 hours ago

Analysts Have Conflicting Sentiments on These Healthcare Companies: Recursion Pharmaceuticals (RXRX), Teladoc (TDOC) and Oscar Health (OSCR)

TIPRANKS
·
20 hours ago

Tempus AI Founder Supports Anthropic CEO’s Call for Slowdown - Bloomberg News

THOMSON REUTERS
·
Yesterday

Tempus AI CEO Sees Healthcare Sector as Biggest AI Beneficiary

Dow Jones
·
Yesterday

Tempus AI to build multimodal whole-genome dataset for AI-driven healthcare

TIPRANKS
·
Sep 11

Tempus AI Launches Effort to Build 100,000 Whole-Genome Dataset Linked to Clinical Outcomes

Reuters
·
Sep 11

Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation

THOMSON REUTERS
·
Sep 11

Tempus AI, - General Availability of Dataset Planned for Mid-2027

THOMSON REUTERS
·
Sep 11

Recursion Pharma CEO Najat Khan Sells 22,408 Shares for $78,822

Reuters
·
Sep 11

Cathie Wood’s ARK Investment buys 271K shares of Beam Therapeutics today

TIPRANKS
·
Sep 10

Tempus AI awarded up to $9.5M from ARPA-H for autonomous AI in cardiology

TIPRANKS
·
Sep 10

Tempus AI Wins up to $9.5 Million ARPA-H Advocate Award for Autonomous Heart Failure Agent

Reuters
·
Sep 10

Tempus Secures up to $9.5 Million in Arpa-H Advocate Funding to Deploy First Autonomous AI in Cardiology

THOMSON REUTERS
·
Sep 10

Tempus AI Initiated at Neutral by UBS

Dow Jones
·
Sep 09

UBS Initiates Coverage on Tempus AI With Neutral Rating, $70 Price Target

MT Newswires Live
·
Sep 09

JonesTrading Remains a Buy on Beam Therapeutics (BEAM)

TIPRANKS
·
Sep 09

Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty Pharma (RPRX)

TIPRANKS
·
Sep 09

Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints

Dow Jones
·
Sep 09